Catalyst
Slingshot members are tracking this event:
Tesaro (TSRO) Plans to Report Phase 3 BRAVO Data in 2H 2017 Evaluating Niraparib in BRCA Positive Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TSRO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 27, 2017
Occurred Source:
https://globenewswire.com/news-release/2017/03/27/945563/0/en/TESARO-Announces-Expanded-Development-Program-for-Niraparib-Focused-on-the-Treatment-of-Front-Line-Metastatic-Ovarian-and-Lung-Cancers-and-Metastatic-Breast-Cancer.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Bravo, Niraparib, Brca Mutation-positive, Breast Cancer
